Related Concept Videos
Tumor Immunotherapy
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
A preserved TGFβ cytostatic response through DLD-mediated metabolic modulation undermines anti-TGFβ therapy in gastric cancer.
Varietal-dependent flavor dynamics in Piper nigrum L. under thermal processing: Unraveling key aroma compounds and processing adaptability mechanisms.
Related Experiment Video
Updated: Nov 26, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors.
Rui Zhang1, Hao-Xiang Wu2, Ming Xu1
1Department of Medical Ultrasound, Division of Interventional Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou, 510080, China.
Mutations in Histone-lysine N-methyltransferase 2 (KMT2) genes are linked to better outcomes for patients receiving immune checkpoint inhibitors (ICI). These KMT2A/C mutations may serve as predictive biomarkers for immunotherapy response in various solid tumors.
Area of Science:
- Oncology
- Immunology
- Epigenetics
Background:
- Epigenetic modifications, including histone methylation by Histone-lysine N-methyltransferase 2 (KMT2) family genes, are crucial in tumor immunology.
- The specific role of KMT2 gene mutations in predicting response to immune checkpoint inhibitors (ICI) remains largely unexplored.
Discussion:
- This study investigates the association between KMT2 gene mutations and clinical benefits from ICI therapy.
- Findings indicate that KMT2A/C mutations correlate with improved progression-free survival (PFS), objective response rate (ORR), durable clinical benefit (DCB), and overall survival (OS) in ICI-treated patients.
- These results were validated in a larger cohort, reinforcing the predictive value of KMT2A/C mutations across diverse cancer subtypes.
Key Insights:
- KMT2A/C mutations are associated with significantly better PFS, ORR, DCB, and OS in patients undergoing ICI treatment.
- The predictive potential of KMT2A/C mutations was confirmed in an independent, larger cohort of ICI-treated individuals.
- Patients with KMT2A/C mutations demonstrated superior OS compared to those with wildtype KMT2A/C, with benefits observed across most solid tumor types.
Outlook:
- KMT2A/C mutations represent a promising novel predictive biomarker for ICI therapy in multiple solid tumors.
- Further research into the underlying mechanisms driving the positive association between KMT2A/C mutations and immunotherapy response is warranted.

